Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, adding:
”Choosing the right anticoagulant for acute venous thromboembolism (VTE) often comes down to balancing efficacy with bleeding risk.
A recent international randomized trial compared apixaban and rivaroxaban, two of the most commonly used direct oral anticoagulants for treating acute pulmonary embolism and proximal deep-vein thrombosis.
Study design
- 2,760 patients with acute symptomatic VTE
- Randomized 1:1 to apixaban or rivaroxaban
- 3-month treatment period
- Primary endpoint: clinically relevant bleeding (major plus clinically relevant non-major bleeding)
Dosing
- Apixaban: 10 mg BID for 7 days – 5 mg BID
- Rivaroxaban: 15 mg BID for 21 days – 20 mg daily
Key results
Clinically relevant bleeding:
- Apixaban: 3.3%
- Rivaroxaban: 7.1%
- Relative risk: 0.46 (95% CI 0.33–0.65, P < 0.001)
This represents ~54% lower risk of clinically relevant bleeding with apixaban over the 3-month treatment period.
Mortality remained very low in both groups
- Apixaban: 0.1%
- Rivaroxaban: 0.3%
Takeaway
Among patients with acute VTE, apixaban demonstrated a significantly lower bleeding risk compared with rivaroxaban, while maintaining similar overall safety outcomes.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger, for the COBRRA Trial Investigators
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation
-
Mar 16, 2026, 17:42Mohamed Sherif Salem: Turning 2026 KDIGO Complexity into Bedside Clarity
-
Mar 16, 2026, 17:39Julie Cardoso: What Happens to Venous Valves When a Blood Clot Forms?
-
Mar 16, 2026, 17:38Nasir Jamal: Blood Transfusion Criteria and Hemodialysis Thresholds in ESRD Patients